The latest price target for Ultragenyx Pharmaceutical (NASDAQ:RARE) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $116.00 expecting RARE to rise to within 12 months (a possible 101.04% upside). 38 analyst firms have reported ratings in the last year.

The latest analyst rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) was provided by Cantor Fitzgerald, and Ultragenyx Pharmaceutical reiterated their overweight rating.

The last upgrade for Ultragenyx Pharmaceutical Inc happened on June 6, 2024 when Goldman Sachs raised their price target to $67. Goldman Sachs previously had a neutral for Ultragenyx Pharmaceutical Inc.

The last downgrade for Ultragenyx Pharmaceutical Inc happened on August 1, 2022 when Evercore ISI Group changed their price target from $95 to $60 for Ultragenyx Pharmaceutical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ultragenyx Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ultragenyx Pharmaceutical was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Ultragenyx Pharmaceutical (RARE) rating was a reiterated with a price target of $116.00 to $116.00. The current price Ultragenyx Pharmaceutical (RARE) is trading at is $57.70, which is out of the analyst’s predicted range.